These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 18855759)

  • 1. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammaactivation.
    Yamagishi S; Matsui T; Nakamura K; Takeuchi M; Inoue H
    Protein Pept Lett; 2008; 15(8):850-3. PubMed ID: 18855759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation.
    Matsui T; Yamagishi S; Ueda S; Nakamura K; Imaizumi T; Takeuchi M; Inoue H
    J Int Med Res; 2007; 35(4):482-9. PubMed ID: 17697525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation.
    Yoshida T; Yamagishi S; Nakamura K; Matsui T; Imaizumi T; Takeuchi M; Koga H; Ueno T; Sata M
    Diabetologia; 2006 Dec; 49(12):3094-9. PubMed ID: 17004092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation.
    Yoshida T; Yamagishi S; Matsui T; Nakamura K; Ueno T; Takeuchi M; Sata M
    J Int Med Res; 2008; 36(2):237-43. PubMed ID: 18380932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
    Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
    Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension.
    Nakamura K; Yamagishi S; Nakamura Y; Takenaka K; Matsui T; Jinnouchi Y; Imaizumi T
    Microvasc Res; 2005 Nov; 70(3):137-41. PubMed ID: 16271939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
    Yamagishi S; Matsui T; Nakamura K; Inoue H; Takeuchi M; Ueda S; Fukami K; Okuda S; Imaizumi T
    Microvasc Res; 2008 Jan; 75(1):130-4. PubMed ID: 17560613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.
    Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
    Biochem Biophys Res Commun; 2009 Jul; 385(2):269-72. PubMed ID: 19460355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan attenuates hyperglycemia-exacerbated VCAM-1 expression and monocytes adhesion in TNFα-stimulated endothelial cells by inhibiting IKKβ expression.
    Song KH; Park JH; Jo I; Park JY; Seo J; Kim SA; Cho DH
    Vascul Pharmacol; 2016 Mar; 78():43-52. PubMed ID: 26455386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
    Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
    Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
    Nakano A; Hattori Y; Aoki C; Jojima T; Kasai K
    Hypertens Res; 2009 Sep; 32(9):765-9. PubMed ID: 19590508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.
    Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
    Biochem Biophys Res Commun; 2010 Jul; 398(2):326-30. PubMed ID: 20599709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telmisartan, a dual ARB/partial PPAR-γ agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes.
    Goyal SN; Bharti S; Bhatia J; Nag TC; Ray R; Arya DS
    Diabetes Obes Metab; 2011 Jun; 13(6):533-41. PubMed ID: 21320264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
    Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
    Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor-gamma activation in mice with chronic cerebral hypoperfusion.
    Washida K; Ihara M; Nishio K; Fujita Y; Maki T; Yamada M; Takahashi J; Wu X; Kihara T; Ito H; Tomimoto H; Takahashi R
    Stroke; 2010 Aug; 41(8):1798-806. PubMed ID: 20595663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
    Toba H; Tojo C; Wang J; Noda K; Kobara M; Nakata T
    Eur J Pharmacol; 2012 Jun; 685(1-3):91-8. PubMed ID: 22314223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
    Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
    Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
    Ikejima H; Imanishi T; Tsujioka H; Kuroi A; Kobayashi K; Shiomi M; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    J Hypertens; 2008 May; 26(5):964-72. PubMed ID: 18398339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telmisartan increases the permeability of endothelial cells through zonula occludens-1.
    Bian C; Wu Y; Chen P
    Biol Pharm Bull; 2009 Mar; 32(3):416-20. PubMed ID: 19252288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.
    Tian Q; Miyazaki R; Ichiki T; Imayama I; Inanaga K; Ohtsubo H; Yano K; Takeda K; Sunagawa K
    Hypertension; 2009 May; 53(5):798-804. PubMed ID: 19289654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.